Abstract

Accrual continues to be a challenge for oncology clinical trials. Interventions to enhance accrual after study activation exist, including corrective action plans for National Cancer Institute sponsored trials. Clinical trials would benefit from a proactive rather than a reactive approach. Accrual strategy planning early in trial development is suggested.